Insider Selling: CeriBell (NASDAQ:CBLL) CEO Sells $786,317.45 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 31,415 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $25.03, for a total value of $786,317.45. Following the sale, the chief executive officer directly owned 787,799 shares of the company’s stock, valued at approximately $19,718,608.97. This represents a 3.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Xingjuan Chao also recently made the following trade(s):

• On Tuesday, August 18th, Xingjuan Chao sold 2,199 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total value of $54,975.00.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $19.90, for a total value of $776,100.00.
• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.33, for a total value of $714,870.00.

CeriBell Price Performance

CeriBell stock opened at $24.20 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The business has a 50 day simple moving average of $19.54 and a 200-day simple moving average of $19.22. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $25.33. The stock has a market capitalization of $928.80 million, a PE ratio of -13.75 and a beta of 0.81.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. Equities analysts predict that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on CBLL shares. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Barclays upgraded shares of CeriBell to a “neutral” rating in a research report on Tuesday. Canaccord Genuity Group lifted their price objective on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Finally, BTIG Research boosted their target price on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, CeriBell has an average rating of “Moderate Buy” and an average price target of $22.40.

Institutional Investors Weigh In On CeriBell

Several institutional investors have recently made changes to their positions in CBLL. Wellington Management Group LLP grew its holdings in shares of CeriBell by 5.5% in the 2nd quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after acquiring an additional 4,572 shares during the period. Formula Growth Ltd. purchased a new stake in CeriBell during the 2nd quarter worth about $603,000. Bank of America Corp DE acquired a new position in shares of CeriBell in the second quarter valued at approximately $4,619,000. PDT Partners LLC acquired a new position in CeriBell in the 2nd quarter valued at $1,026,000. Finally, Legal & General Group Plc purchased a new position in CeriBell during the second quarter worth about $53,000.

Key CeriBell News

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Analyst price targets increased. BTIG Research raised its target from $28 to $30 and reiterated a Buy rating, while Canaccord Genuity lifted its target from $25 to $26 and also maintained a Buy rating. These revisions indicate continued confidence in CeriBell’s growth prospects. CeriBell Stock Price Expected to Rise, BTIG Research Analyst Says
• Positive Sentiment: Institutional interest has been supportive. TimesSquare Capital Management initiated a position valued at approximately $15.2 million, while KCM Capital increased its holdings by 40% to 1.4 million shares. Additional firms also established or expanded positions, suggesting some professional investors see value in CBLL.
• Neutral Sentiment: Recent financial results were mixed. CeriBell’s quarterly revenue of $28.1 million exceeded the $27.28 million consensus estimate, but its $0.51 per-share loss was wider than the expected $0.47 loss. The company remains unprofitable, and analysts expect a full-year loss of approximately $1.96 per share.
• Neutral Sentiment: Analyst opinion remains generally favorable but valuation expectations are uneven. The consensus rating is “Moderate Buy,” although the average target of $22.40 is below the recent trading level. Barclays upgraded the stock to Neutral, reflecting a more cautious stance.
• Negative Sentiment: Senior executives sold a substantial number of shares. CEO Xingjuan Chao sold 33,614 shares for about $841,000 across August 18–19, reducing her holdings by roughly 4%. CFO Scott Blumberg sold 34,502 shares for approximately $864,000, cutting his direct ownership by about 18.45%. The transactions occurred around $25 per share, close to CeriBell’s 52-week high, and could be interpreted as profit-taking or a potential near-term confidence signal. CeriBell Insider Trading Activity

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.